Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date Issued: November 13, 2023
Subject: Announcement of a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the drug momelotinib.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Developments
- CHMP Opinion: The EMA's CHMP has adopted a positive opinion recommending approval of momelotinib for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis, or post essential thrombocythaemia myelofibrosis.
- Target Population: The indication covers patients who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
- Market Position: If approved, momelotinib would be the first and only treatment in the EU specifically indicated for both newly diagnosed and previously treated myelofibrosis patients with moderate to severe anaemia that addresses splenomegaly and symptoms.
- Timeline: A decision on EU marketing authorisation is expected by early 2024.
- Trade Name: The proposed trade name in the EU is Omjjara.
Outlook, Management Commentary, and Risks
Management Commentary
Nina Mojas, Senior Vice President of Oncology Global Product Strategy, stated that momelotinib has a differentiated mechanism of action addressing significant medical needs, particularly for patients with moderate to severe anaemia who often require transfusions or discontinue treatment. The positive opinion is described as a significant step in bringing the drug to EU patients.
Clinical Data Support
The opinion is supported by data from:
- MOMENTUM Study: A phase III trial evaluating momelotinib versus danazol in JAK inhibitor-experienced patients. It met primary endpoints for constitutional symptoms, splenic response, and transfusion independence.
- SIMPLIFY-1 Trial: A phase III trial comparing momelotinib to ruxolitinib in JAK inhibitor-naïve patients, with efficacy based on a subset of patients with anaemia.
Risks and Contingencies
The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in the company's Annual Report on Form 20-F for 2022 and Q3 Results for 2023. Final marketing authorisation is subject to a decision by the European Commission.
Investor Verification Checklist
- Confirm the final marketing authorisation decision by the European Commission, expected in early 2024.
- Verify the commercial launch timeline and pricing strategy for Omjjara in the EU market.
- Review the specific patient eligibility criteria for the EU indication compared to the existing US FDA approval (Ojjaara).
- Monitor post-marketing safety data, noting common adverse reactions such as diarrhoea, thrombocytopaenia, and nausea.
- Assess the competitive landscape in the EU for myelofibrosis treatments, specifically regarding JAK inhibitors.